Coming up on May 11th: BDI’s Social Communications & Healthcare event – half day session in NYC with Case Studies and Roundtables (I’ll be leading one of the roundtables). Top speakers from J&J, Pfizer, and more! These are always great networking and learning events. Hope to see you there!
For more information, including registration, please click here to visit the event website. Use promo code IMPACT for a discounted rate of $155.
In Celgene‘s pipeline – a promising oral RA (Rheumatoid Arthritis) treatment – Celgene Corp. believes sales of lead development candidate Apremilast will be $2 billion to $3 billion a year in psoriasis and psoriatic arthritis. The drug, which would compete with some of the world’s biggest selling therapies, is expected to enter late-stage trials this year and could be launched in 2014 or 2015, the company said. The projection came during the Summit, N.J., drug maker’s research and development presentation in New York Thursday…more But, not such good news about low-dose aspirin as a RA preventative.
Oh, by the way – there were a few suicides, too. How not to get approval for Daxas (Forest Labs).
The arguments begin the Novartis discrimination lawsuit. How many isolated incidents indicate a systemic problem? This one’s going to get sticky…
Letting Go. A challenge to think differently.
Diversity/Ethics training– We can recommend best-in-class partners and programs for your needs. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
“Compulsive Generosity” due to Parkinson’s Rx – an embezzler gets off with an imaginative “the drug made me do it” plea. Ludicrous.
JUST FOR FUN
The Enlightened Stupid Marketer. 3 1/2 minutes of fun with Kevin Nalts.
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board